108 related articles for article (PubMed ID: 7563593)
21. [Low-dose cytosine arabinoside and aclarubicin in combination with granulocyte colony-stimulating factor for the treatment of relapsed acute myeloid leukemia].
Saito K
Rinsho Ketsueki; 1996 Aug; 37(8):651-3. PubMed ID: 8827872
[TBL] [Abstract][Full Text] [Related]
22. ["AB-Triple V" therapy of relapsed or refractory acute myelogenous leukemia].
Asou N; Suzushima H; Hamasaki N; Goto J; Hidaka M; Akagi K; Kurisaki H; Sawatari T; Kawano F; Takatsuki K
Rinsho Ketsueki; 1989 Feb; 30(2):169-74. PubMed ID: 2746873
[TBL] [Abstract][Full Text] [Related]
23. [Refractory acute myelogenous leukemia successfully treated with a continuous infusion chemotherapy of low dose aclarubicin and cytosine arabinoside: a case report].
Kawada H; Komatsuda M; Masumoto A; Fukuda R; Watanabe S; Yonekura S; Ichikawa Y; Nagao T; Arimori S
Rinsho Ketsueki; 1993 May; 34(5):667-9. PubMed ID: 8315839
[TBL] [Abstract][Full Text] [Related]
24. [Trial of combined cytosine arabinoside with granulocyte colony-stimulating factor therapy or refractory acute myeloid leukemia].
Mori H; Kuriyama K; Tawara M; Danno Y; Fujimoto K; Tushima H; Saito M; Yamamura M; Hata T; Arimura M
Rinsho Ketsueki; 1995 Jul; 36(7):648-56. PubMed ID: 7563592
[TBL] [Abstract][Full Text] [Related]
25. Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
Sung WJ; Kim DH; Sohn SK; Kim JG; Baek JH; Jeon SB; Moon JH; Ahn BM; Lee KB
Jpn J Clin Oncol; 2005 Oct; 35(10):612-6. PubMed ID: 16172175
[TBL] [Abstract][Full Text] [Related]
26. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
[TBL] [Abstract][Full Text] [Related]
27. Sequential standard dose mitoxantrone and cytosine arabinoside for newly diagnosed adult acute myeloblastic leukemia.
Al Bahar S; Pandita R; Bavishi K; Savani B
Neoplasma; 1999; 46(1):61-5. PubMed ID: 10355536
[TBL] [Abstract][Full Text] [Related]
28. Combination therapy with mitoxantrone and etoposide in refractory acute myelogenous leukemia.
Ho AD; Lipp T; Ehninger G; Meyer P; Freund M; Hunstein W
Cancer Treat Rep; 1986 Aug; 70(8):1025-7. PubMed ID: 3460698
[TBL] [Abstract][Full Text] [Related]
29. Idarubicin/cytosine arabinoside and mitoxantrone/etoposide for the treatment of de novo acute myelogenous leukemia.
Haas R; Ho AD; Del Valle F; Fischer JT; Ehrhardt R; Döhner H; Witt B; Huberts H; Kaplan E; Hunstein W
Semin Oncol; 1993 Dec; 20(6 Suppl 8):20-6. PubMed ID: 8290968
[TBL] [Abstract][Full Text] [Related]
30. A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial.
Vogler WR; McCarley DL; Stagg M; Bartolucci AA; Moore J; Martelo O; Omura GA
Leukemia; 1994 Nov; 8(11):1847-53. PubMed ID: 7967730
[TBL] [Abstract][Full Text] [Related]
31. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
32. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
Yavuz S; Paydas S; Disel U; Sahin B
Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
[TBL] [Abstract][Full Text] [Related]
33. [Etoposide (VP 16/NK 171) and cytosine arabinoside combination chemotherapy in refractory childhood leukemia].
Esumi N; Todo S; Arakawa S; Imashuku S
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):951-8. PubMed ID: 3963859
[TBL] [Abstract][Full Text] [Related]
34. BAVC regimen and autograft for acute myelogenous leukemia in second complete remission.
Meloni G; Vignetti M; Avvisati G; Capria S; Micozzi A; Giona F; Mandelli F
Bone Marrow Transplant; 1996 Oct; 18(4):693-8. PubMed ID: 8899182
[TBL] [Abstract][Full Text] [Related]
35. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-2 therapy in relapsed acute myelogenous leukemia.
Meloni G; Vignetti M; Pogliani E; Invernizzi R; Allione B; Mirto S; Sica S; Leoni F; Selleri C; Mandelli F
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S43-7. PubMed ID: 9457393
[TBL] [Abstract][Full Text] [Related]
37. Results of treatment with an intensive combination induction regimen containing idarubicin in children with acute myeloblastic leukemia: preliminary report of the Argentine Group for Treatment of Acute Leukemia.
Sackmann-Muriel F; Fernández-Barbieri MA; Santarelli MT; Matus-Ridley M; Rosso A; Negri-Aranguren P; Cerutti I; Gomel M; Kvicala R
Semin Oncol; 1993 Dec; 20(6 Suppl 8):34-8. PubMed ID: 8290970
[TBL] [Abstract][Full Text] [Related]
38. Induction chemotherapy with idarubicin plus N4-behenoyl-1-beta-D-arabinofuranosylcytosine in acute myelogenous leukemia: a newly designed induction regimen--a prospective, cooperative multicenter study.
Park HS; Kim DW; Kim CC; Kim HK; Kim JS; Hwang TJ; Kim HJ; Kim HS; Song HS; Park JW; Ahn HS; Chung TJ; Cho KS; Lee KS; Choi YM
Semin Hematol; 1996 Oct; 33(4 Suppl 3):24-9. PubMed ID: 8916313
[TBL] [Abstract][Full Text] [Related]
39. [Therapeutic effects of a combination of intermediate-dose cytosine arabinoside, adriamycin and vincristine in relapsed acute leukemia].
Takahashi I; Yorimitsu S; Inagaki T; Sekito N; Hayashi N; Nishimura M; Aoyama S; Nakada H; Ohmoto E; Uchida K
Gan To Kagaku Ryoho; 1987 Feb; 14(2):485-9. PubMed ID: 3813576
[TBL] [Abstract][Full Text] [Related]
40. [Clinical study on regimen cyclophosphamide, Ara-C and topotecan (CAT) in treatment of patients with refractory or relapsed acute myelogenous leukemia].
Qin TJ; Xu ZF; Wang JY; Zhou CL; Xiao ZJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Oct; 17(5):1342-6. PubMed ID: 19840480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
